Company Filing History:
Years Active: 1989
Title: Luc Rivron: Innovator in Biomarker Detection
Introduction
Luc Rivron is a notable inventor based in France, recognized for his contributions to the field of biomarker detection. His work primarily focuses on the use of specific compounds to identify peripheral benzodiazepine receptor (PBR) levels in individuals. Despite having no patents registered under his name, Rivron's research has significant implications for both normal and pathological conditions.
Latest Patents
Rivron's notable patent involves the use of 7-Chloro-N,N,5-Trimethyl-4-Oxo-3-Phenyl-3,5-Dihydro-4H-Pyridazino[4,5-B]indole-1-Acetamide as a biomarker for detecting PBR levels. This innovative method includes a radiolabelled form of the compound, which serves as a diagnostic tool for assessing PBR levels associated with various health conditions. The patent outlines a method for detection and the development of a diagnostic kit, showcasing Rivron's commitment to advancing medical diagnostics.
Career Highlights
Throughout his career, Luc Rivron has worked with prominent organizations, including Sanofi-Aventis and the Commissariat à l'Énergie Atomique (CEA). His experience in these institutions has allowed him to collaborate with leading experts in the field, further enhancing his research capabilities and contributions to biomarker detection.
Collaborations
Rivron has collaborated with notable colleagues such as Jesus Benavides and Herve Boutin. These partnerships have played a crucial role in the development of his research and the advancement of diagnostic methods in the medical field.
Conclusion
Luc Rivron's work in biomarker detection represents a significant advancement in medical diagnostics. His innovative approach to identifying PBR levels has the potential to improve health assessments and contribute to better patient outcomes.